Celldex Therapeutics (CLDX) Depreciation & Amortization (CF) (2010 - 2026)

Celldex Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $854000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 1.5% year-over-year to $854000.0; the TTM figure through Mar 2026 stood at $3.4 million (up 3.0% YoY), while the FY2025 annual figure was $3.4 million, up 6.39% from the prior year.
• Depreciation & Amortization (CF) was $854000.0 for Q1 2026 at Celldex Therapeutics, up from $816000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $873000.0 in Q2 2025 to a low of $671000.0 in Q3 2022.
• Historically, Depreciation & Amortization (CF) has averaged $783235.3 across 5 years, with a median of $786000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) declined 13.38% in 2022, then grew 14.31% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $673000.0 in 2022, then rose by 12.78% to $759000.0 in 2023, then gained by 7.91% to $819000.0 in 2024, then retreated by 0.37% to $816000.0 in 2025, then increased by 4.66% to $854000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $854000.0 (Q1 2026), $816000.0 (Q4 2025), and $824000.0 (Q3 2025), per Business Quant data.